SHR-7787 for Advanced Solid Tumors

This clinical study is focused on patients with advanced solid tumors, aiming to assess a new treatment called SHR-7787. The primary goal is to determine how safe and tolerable this drug is when used alone, as well as to understand how the body processes it and whether it can effectively treat the tumors. By exploring the most suitable dosage, the study seeks to find out if SHR-7787 can become a viable treatment option, potentially offering hope for patients whose tumors are not responding to existing therapies. Participants in the study will receive SHR-7787 through an injection. Researchers will closely monitor the patients to observe any side effects and how well they tolerate the drug. They will also measure how the body absorbs, distributes, and eliminates the drug to understand its pharmacokinetics. While there are no specific outcomes listed, the study will likely evaluate changes in tumor size or progression to gauge the drug's effectiveness. Participants should be informed about potential risks and benefits, though specific details on these are not provided in the available information.